DocCheck AG's recent 12% share price increase offers hope after a 61% decline over three years. Despite falling EPS, the market may be undervaluing the company. CEO's modest pay and TSR of -54% indicate room for improvement.
Read MoreDid you find this insightful?
Amazing
Bad
Just Okay